WAYNE, Pa., May 9, 2014 /PRNewswire/ -- Ryan & Maniskas,
LLP is investigating potential claims against the board of
directors of Chelsea Therapeutics International Ltd. ("Chelsea
Therapeutics" or the "Company") (NASDAQ: CHTP) concerning possible
breaches of fiduciary duty and other violations of law related to
the Company's efforts to sell the Company to H. Lundbeck A/S in a
transaction valued at approximately $658
million.
If you own shares of Chelsea Therapeutics and would like to
learn more about this class action or if you wish to discuss these
matters and have any questions concerning this announcement or your
rights, contact Richard A. Maniskas,
Esquire toll-free at (877) 316-3218 or to sign up online,
visit: www.rmclasslaw.com/cases/chtp. You may also email Mr.
Maniskas at rmaniskas@rmclasslaw.com.
Under the terms of the agreement, shareholders of Chelsea
Therapeutics would receive $6.44 in
cash, and up to $1.50 per share in a
Contingent Value Right, for each share of Chelsea Therapeutics they
own.
Our investigation concerns possible breaches of fiduciary duty
and other violations of state law by the Board of Directors of
Chelsea Therapeutics for not acting in the Company's shareholders'
best interests in connection with the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide. To learn more
about the class action process, please visit:
www.rmclasslaw.com.
CONTACT:
|
Ryan & Maniskas,
LLP
|
|
Richard A. Maniskas,
Esquire
|
|
995 Old Eagle School
Rd., Suite 311
|
|
Wayne, PA
19087
|
|
877-316-3218
|
|
www.rmclasslaw.com/cases/chtp
|
|
rmaniskas@rmclasslaw.com
|
Logo -
http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
SOURCE Ryan & Maniskas, LLP